BlueStar
FDA-cleared digital therapeutic for type 1 and type 2 diabetes management
Company profile
Company profile
WellDoc is a digital health company that transforms fragmented cardiometabolic data into actionable insights through clinically-validated AI technology. The company's platform serves as a bridge connecting members, care teams, and healthcare partners with personalized, predictive solutions built for real-world healthcare delivery. WellDoc's core technology analyzes over 680 unique metrics across 80 health domains annually per user, powered by half a billion data points, to deliver truly personalized health management. The company offers multiple solutions including FDA-cleared medical devices for type 1 and type 2 diabetes management, comprehensive weight management programs (including GLP-1 medication support), and broader cardiometabolic health solutions. WellDoc's platform integrates seamlessly with existing healthcare infrastructure through flexible partnership models, supporting branded and white-label implementations, companion apps for pharmaceutical and medical device companies, and direct integrations via SDK or API. With 11 FDA 510(k) clearances, 67 patents, and over 100 clinical publications, WellDoc has established itself as a leader in regulatory-grade digital health technology. The platform currently supports 53 million covered lives and connects to 400+ devices and data sources. WellDoc serves multiple customer segments including life sciences and medtech companies, health plans and PBMs, employers, healthtech companies, DMEs, and health systems. The company partners with major healthcare organizations including CVS Health and Eli Lilly to deliver proven outcomes in chronic disease management.
Company description WellDoc official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Api Only · Cloud Saas deployment with recorded integration context.
Recorded integration context: 400+ connected devices including CGMs, scales, blood pressure cuffs, DTC services, EHR systems, Existing healthcare portals and proprietary applications, Pharmacy connectivity.
Company milestones
Named 'Best Overall Digital Health Company' for 4th consecutive year in MedTech Breakthrough Awards (2025). Launched personalized companion app for leading life sciences company supporting incretin-based therapies. Currently supports 53 million covered lives.
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
FDA-cleared digital therapeutic for type 1 and type 2 diabetes management
Customizable companion apps for life sciences and medtech companies
Turn-key weight management program combining Welldoc AI with virtual clinical support
FDA-cleared prescription digital therapeutic for diabetes management
Healthcare-ready AI platform transforming cardiometabolic data into actionable insights
Complete weight management solution integrating GLP-1s, behavior change, and AI
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Journal of diabetes science and technology · May 1, 2025
Comorbidities And Reducing InEquitieS (CARES): Feasibility of self-monitoring and community health worker support in management of comorbidities among Black breast and prostate cancer patients.Contemporary clinical trials communications · Feb 1, 2025
Safety of a Novel Continuous Glucose Monitoring-Informed Insulin Bolus Calculator Mobile Application for People With Type 1 or Type 2 Diabetes.Diabetes spectrum : a publication of the American Diabetes Association · Jan 1, 2025
Personalized cardiometabolic care powered by artificial intelligence.Frontiers in endocrinology · Jan 1, 2025
The critical elements of digital health in diabetes and cardiometabolic care.Frontiers in endocrinology · Jan 1, 2024
Association-Industry Collaboration: 50 Years of Innovating Diabetes Care.The science of diabetes self-management and care · Aug 1, 2023
Clinical validation
NCT07633171 · Sponsor · NOT YET RECRUITING
Regulatory
K190013 · 510k · Nov 4, 2019
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
CVS Healthspire weight management program
Program members taking anti-obesity medication for one year
Enhanced weight management program
Weight management program participants
Weight management program for members using anti-obesity medications
Up to 47% less client spend on anti-obesity medication, 18.5% average weight loss for program members taking AOM, 2:1 observed ROI, 92% member satisfaction
Personalized companion app for individuals using incretin-based therapies for cardiometabolic support
Comprehensive cardiometabolic support with medication reminders, dose logging and device connectivity
05 · Leadership
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Recent articles published on WellDoc's official website.
No Company updates are currently listed.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies using AI and digital health tools to help patients manage chronic conditions through digital therapeutics, gamified health management, and AI-powered coaching. Covers management of all chronic diseases including diabetes, hypertension, COPD, heart disease, and multi-condition platforms. Includes continuous glucose monitoring (CGM) systems with AI analytics and insulin optimization algorithms.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.